Evaluation of pancreatic carcinoma with FDG PET

AbstractBackground: To assess the diagnostic usefulness and clinical impact of positron emission tomography with [F-18]fluorodeoxyglucose (FDG PET) on the management of patients with known or suspected pancreatic carcinoma. Methods: Attenuation-corrected FDG PET was performed in 20 patients (12 male, eight female) with pancreatic carcinoma at the time of initial diagnosis (n = 7), for tumor surveillance after Whipple surgery (n = 11), and for reevaluation after chemoradiation therapy (n = 2). Visual analysis of PET images were correlated with the results of abdominal computed tomography (CT) and carbohydrate antigen (CA) 19-9 serum tumor marker level that were obtained within 1 month of the PET study. Diagnostic validation was by histology in nine patients and by clinical or radiologic follow-up (5–48 months) in 11 patients. Changes in therapeutic management that were prompted by PET were tabulated. Results: PET was concordant with the findings of abdominal CT in 14 patients (13 true positive, 1 true negative). PET detected clinically unsuspected lung lesions, confirmed subsequently by a chest CT, in one of these 14 patients. PET was discordant with CT in six patients. PET detected tumor recurrence in three patients in this group (15% of total) with nondiagnostic CT findings and elevated CA 19-9 serology. In two of these three patients, chemotherapy with gemcitabine was initiated based on PET localization of disease. Tumor was confirmed in the remaining one of the three patients at autopsy shortly after the PET study. FDG localization in a displaced loop of bowel resulted in an apparent false-positive hepatic lesion in one of six patients in the discordant group. PET underestimated the extent of metastatic disease in the remaining two of six patients due to hyperglycemia. Conclusion: In patients with suspected pancreatic carcinoma at the time of initial presentation, PET is complementary to abdominal CT and allows detection of unsuspected distant metastases. In patients with suspected recurrent pancreatic carcinoma, based on elevated or rising CA 19-9 serology, PET can localize the disease when abdominal CT is nondiagnostic as a result of posttherapy anatomic alteration. Imaging evaluation with PET may impact the clinical management of patients with pancreatic carcinoma.

[1]  W. Steinberg The clinical utility of the CA 19-9 tumor-associated antigen. , 1990, The American journal of gastroenterology.

[2]  Y. Yonekura,et al.  Evaluation of pancreatic tumors with positron emission tomography and F-18 fluorodeoxyglucose: comparison with CT and US. , 1995, Radiology.

[3]  Scott T. Grafton,et al.  PET and [18F]-FDG in oncology: a clinical update. , 1996, Nuclear medicine and biology.

[4]  H. Gogas,et al.  Are serial measurements of CA19-9 useful in predicting response to chemotherapy in patients with inoperable adenocarcinoma of the pancreas? , 1998, British Journal of Cancer.

[5]  G. Glatting,et al.  FDG PET: elevated plasma glucose reduces both uptake and detection rate of pancreatic malignancies. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[6]  H. Jadvar,et al.  Effect of atropine and sincalide on the intestinal uptake of F-18 fluorodeoxyglucose. , 1999, Clinical nuclear medicine.

[7]  L. Traverso,et al.  Pancreatic ductal adenocarcinoma: diagnosis and staging with dynamic CT. , 1988, Radiology.

[8]  S. Hauptmann,et al.  Pancreatic cancer detected by positron emission tomography with 18F-labelled deoxyglucose: method and first results. , 1993, Nuclear medicine communications.

[9]  L. Adler,et al.  Elimination of artifactual accumulation of FDG in PET imaging of colorectal cancer. , 1998, Clinical nuclear medicine.

[10]  D. V. Von Hoff,et al.  A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. , 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

[11]  F. Safi,et al.  The clinical relevance of the tumor marker CA 19-9 in the diagnosing and monitoring of pancreatic carcinoma. , 1990, Bulletin du cancer.

[12]  G. Glatting,et al.  Overexpression of glucose transporter 1 and increased FDG uptake in pancreatic carcinoma. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[13]  S. Sironi,et al.  Pancreatic cancer versus chronic pancreatitis: diagnosis with CA 19-9 assessment, US, CT, and CT-guided fine-needle biopsy. , 1991, Radiology.

[14]  A. Mariani,et al.  Serum CA 19‐9 in the postsurgical follow‐up of patients with pancreatic cancer , 1987, Cancer.

[15]  L. Griffeth,et al.  FDG-PET evaluation of indeterminate pancreatic masses. , 1996, Journal of computer assisted tomography.

[16]  H. Friess,et al.  Diagnosis of pancreatic cancer by 2[18F]-fluoro-2-deoxy-D-glucose positron emission tomography. , 1995, Gut.

[17]  D. Pleskow,et al.  Evaluation of a serologic marker, CA19-9, in the diagnosis of pancreatic cancer. , 1989, Annals of internal medicine.

[18]  U. Buell,et al.  18FDG-positron emission tomography in pancreatic cancer. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[19]  B. Siewert,et al.  Teardrop superior mesenteric vein: CT sign for unresectable carcinoma of the pancreas. , 1999, AJR. American journal of roentgenology.

[20]  Stephens Cd Gemcitabine: a new approach to treating pancreatic cancer. , 1998 .

[21]  P. Robinson,et al.  Dynamic contrast-enhanced MR imaging and dual-phase helical CT in the preoperative assessment of suspected pancreatic cancer: a comparative study with receiver operating characteristic analysis. , 1999, AJR. American journal of roentgenology.

[22]  S. Hauptmann,et al.  F-18 fluorodeoxyglucose PET in vivo evaluation of pancreatic glucose metabolism for detection of pancreatic cancer. , 1994, Radiology.

[23]  R. Bares,et al.  PET with fluorine-18 deoxyglucose for pancreatic disease , 1992, The Lancet.

[24]  K. Brandt,et al.  CT- and US-guided biopsy of the pancreas. , 1993, Radiology.

[25]  P. Shreve Focal fluorine-18 fluorodeoxyglucose accumulation in inflammatory pancreatic disease , 1998, European Journal of Nuclear Medicine.

[26]  B. Wood,et al.  Adenocarcinoma of the head of the pancreas: determination of surgical unresectability with thin-section pancreatic-phase helical CT. , 1999, AJR. American journal of roentgenology.

[27]  H. Friess,et al.  2-(fluorine-18)-fluoro-2-deoxy-D-glucose PET in detection of pancreatic cancer: value of quantitative image interpretation. , 1995, Radiology.

[28]  R. Coleman,et al.  Diagnosis of pancreatic carcinoma: role of FDG PET. , 1998, AJR. American journal of roentgenology.

[29]  Y. Nishimura,et al.  Evaluation of intraoperative radiation therapy for unresectable pancreatic cancer with FDG PET. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[30]  W. Chapman,et al.  Optimal interpretation of FDG PET in the diagnosis, staging and management of pancreatic carcinoma. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[31]  D. V. Von Hoff,et al.  Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.